Alector, Inc. (ALEC) Spending and interest coverage
- R&D / revenue · 12 months: Value 715.07%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 120.92%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 715.07% | Research and development expense / revenue. Period ending 2026-06-30. $99.13M ÷ $13.86M × 100 ≈ 715.07% |
| Stock-based compensation / revenue · 12 months | 120.92% | Share-based compensation / revenue. Period ending 2026-06-30. $16.76M ÷ $13.86M × 100 ≈ 120.92% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 99.13M USD | Research and Development Expense |
| Revenue | 13.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 16.76M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -126.49M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $99.13M | $13.86M | $16.76M | $-126.49M | (m) | 715.07% | 120.92% | (m) | (m) |
| 2026-03-31 | $107.28M | $18.42M | $21.21M | $-136.23M | (m) | 582.51% | 115.19% | (m) | (m) |
| 2025-12-31 | $123.06M | $21.05M | $26.66M | $-156.01M | (m) | 584.77% | 126.67% | (m) | (m) |
| 2025-09-30 | $137.06M | $69.05M | $32.03M | $-123.69M | (m) | 198.50% | 46.38% | (m) | (m) |
| 2025-06-30 | $155.71M | $81.13M | $34.66M | $-134.52M | (m) | 191.93% | 42.72% | (m) | (m) |
| 2025-03-31 | $174.41M | $88.34M | $37.51M | $-145.98M | (m) | 197.44% | 42.46% | (m) | (m) |
| 2024-12-31 | $185.94M | $100.56M | $39.46M | $-145.00M | (m) | 184.91% | 39.24% | (m) | (m) |
| 2024-09-30 | $187.20M | $61.51M | $40.79M | $-185.20M | (m) | 304.35% | 66.32% | (m) | (m) |
| 2024-06-30 | $185.53M | $55.27M | $41.82M | $-187.35M | (m) | 335.65% | 75.65% | (m) | (m) |
| 2024-03-31 | $185.40M | $96.41M | $42.13M | $-145.33M | (m) | 192.31% | 43.70% | (m) | (m) |
| 2023-12-31 | $192.12M | $97.06M | $42.80M | $-151.74M | (m) | 197.93% | 44.09% | (m) | (m) |
| 2023-09-30 | $198.88M | $96.31M | $42.22M | $-159.72M | (m) | 206.50% | 43.84% | (m) | (m) |
| 2023-06-30 | $200.91M | $102.06M | $42.93M | $-156.89M | (m) | 196.86% | 42.06% | (m) | (m) |
| 2023-03-31 | $209.26M | $125.69M | $45.18M | $-143.83M | (m) | 166.49% | 35.95% | (m) | (m) |
| 2022-12-31 | $210.42M | $133.62M | $46.15M | $-137.83M | (m) | 157.48% | 34.54% | (m) | (m) |
| 2022-09-30 | $208.72M | $133.17M | $47.89M | $-138.13M | (m) | 156.73% | 35.96% | (m) | (m) |
| 2022-06-30 | $203.43M | $300.73M | $47.32M | $35.95M | (m) | 67.65% | 15.74% | (m) | (m) |
| 2022-03-31 | $196.72M | $227.45M | $43.92M | $-28.85M | (m) | 86.49% | 19.31% | (m) | (m) |
| 2021-12-31 | $189.41M | $207.09M | $40.78M | $-37.36M | (m) | 91.46% | 19.69% | (m) | (m) |
| 2021-09-30 | $181.00M | $197.94M | $36.98M | $-34.39M | (m) | 91.44% | 18.68% | (m) | (m) |
| 2021-06-30 | $181.75M | $21.43M | $34.81M | $-214.47M | (m) | 847.93% | 162.40% | (m) | (m) |
| 2021-03-31 | $168.00M | $18.04M | $32.68M | $-205.73M | (m) | 931.40% | 181.18% | (m) | (m) |
| 2020-12-31 | $156.87M | $21.10M | $30.52M | $-195.17M | (m) | 743.53% | 144.67% | (m) | (m) |
| 2020-09-30 | $138.25M | $22.25M | $26.86M | $-174.76M | (m) | 621.45% | 120.73% | (m) | (m) |
| 2020-06-30 | $122.95M | $19.04M | $22.93M | $-155.16M | (m) | 645.80% | 120.45% | (m) | (m) |
| 2020-03-31 | $114.53M | $22.79M | $19.68M | $-135.72M | (m) | 502.64% | 86.36% | (m) | (m) |
| 2019-12-31 | $100.53M | $21.22M | $16.28M | $-114.40M | (m) | 473.76% | 76.73% | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $73.03M | $27.51M | $6.92M | $-57.29M | (m) | 265.49% | 25.17% | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $29.91M | $2.87M | $5.35M | $-32.68M | (m) | 1041.47% | 186.42% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |